Trinity Biotech revenue comes in light

Trinity Biotech (TRIB -3.1%) Q2: Diluted EPS (ex-Medical Devise Excise Tax) of $0.176.

Revenue of $21.3M (+2.4% Y/Y) misses by $0.7M.

The company also says it is acquiring Immco Diagnostics for $32.75M, a deal TRIB says will be "immediately earnings accretive." (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs